短发夹RNA介导的人呼吸道合胞病毒基质基因沉默作为一种有效的抗病毒策略

IF 2.1 4区医学 Q3 VIROLOGY

Future Virology Pub Date : 2023-05-16 DOI:10.2217/fvl-2022-0207

Saeid Amiri Zadeh Fard, Haniyeh Abuei, A. Farhadi, Gholamreza Rafiei Dehbidi, F. Zare, Zahra Abbasfard, A. Behbahani

{"title":"短发夹RNA介导的人呼吸道合胞病毒基质基因沉默作为一种有效的抗病毒策略","authors":"Saeid Amiri Zadeh Fard, Haniyeh Abuei, A. Farhadi, Gholamreza Rafiei Dehbidi, F. Zare, Zahra Abbasfard, A. Behbahani","doi":"10.2217/fvl-2022-0207","DOIUrl":null,"url":null,"abstract":"Aim: Human respiratory syncytial virus (HRSV) is a common cause of respiratory infections, particularly in infants and the elderly. Ribavirin is the only US FDA-approved antiviral drug for HRSV infection, but it has unwanted side effects. Methods: We engineered an shRNA targeting the HRSV- M gene to antagonize HRSV replication. Results: The results showed that shRNA had a similarly significant reduction in viral load (99.8%) as ribavirin. In addition, combined treatment with ribavirin and M-shRNA resulted in a significant reduction in viral load compared with ribavirin or M-shRNA alone. Conclusion: These results suggest that M-shRNA could be a potential new inhibitor of HRSV replication and could offer a safer and more effective treatment option for HRSV infection in the future.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2023-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Short hairpin RNA-mediated matrix gene silencing of human respiratory syncytial virus as a potent antiviral strategy\",\"authors\":\"Saeid Amiri Zadeh Fard, Haniyeh Abuei, A. Farhadi, Gholamreza Rafiei Dehbidi, F. Zare, Zahra Abbasfard, A. Behbahani\",\"doi\":\"10.2217/fvl-2022-0207\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: Human respiratory syncytial virus (HRSV) is a common cause of respiratory infections, particularly in infants and the elderly. Ribavirin is the only US FDA-approved antiviral drug for HRSV infection, but it has unwanted side effects. Methods: We engineered an shRNA targeting the HRSV- M gene to antagonize HRSV replication. Results: The results showed that shRNA had a similarly significant reduction in viral load (99.8%) as ribavirin. In addition, combined treatment with ribavirin and M-shRNA resulted in a significant reduction in viral load compared with ribavirin or M-shRNA alone. Conclusion: These results suggest that M-shRNA could be a potential new inhibitor of HRSV replication and could offer a safer and more effective treatment option for HRSV infection in the future.\",\"PeriodicalId\":12505,\"journal\":{\"name\":\"Future Virology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2023-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Virology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/fvl-2022-0207\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"VIROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Virology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/fvl-2022-0207","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的:人呼吸道合胞病毒(HRSV)是呼吸道感染的常见原因，特别是在婴儿和老年人中。利巴韦林是美国fda批准的唯一一种治疗HRSV感染的抗病毒药物，但是它有副作用。方法:我们设计了一种靶向HRSV- M基因的shRNA来对抗HRSV的复制。结果:结果表明shRNA与利巴韦林具有相似的显著的病毒载量降低(99.8%)。此外，与单独使用利巴韦林或M-shRNA相比，利巴韦林和M-shRNA联合治疗可显著降低病毒载量。结论:这些结果提示M-shRNA可能是一种潜在的新的HRSV复制抑制剂，并可能在未来为HRSV感染提供更安全、更有效的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Short hairpin RNA-mediated matrix gene silencing of human respiratory syncytial virus as a potent antiviral strategy

Aim: Human respiratory syncytial virus (HRSV) is a common cause of respiratory infections, particularly in infants and the elderly. Ribavirin is the only US FDA-approved antiviral drug for HRSV infection, but it has unwanted side effects. Methods: We engineered an shRNA targeting the HRSV- M gene to antagonize HRSV replication. Results: The results showed that shRNA had a similarly significant reduction in viral load (99.8%) as ribavirin. In addition, combined treatment with ribavirin and M-shRNA resulted in a significant reduction in viral load compared with ribavirin or M-shRNA alone. Conclusion: These results suggest that M-shRNA could be a potential new inhibitor of HRSV replication and could offer a safer and more effective treatment option for HRSV infection in the future.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Virology 医学-病毒学

CiteScore

4.00

自引率

3.20%

发文量

审稿时长

6-12 weeks

期刊介绍： Future Virology is a peer-reviewed journal that delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this ever-expanding area of research. It is an interdisciplinary forum for all scientists working in the field today.